The FDA approved ensartinib (Ensacove) as a first-line treatment for adults with ALK -positive locally advanced or metastatic ...

Ensartinib has received FDA approval for the first-line treatment of ALK-positive locally advanced or metastatic non–small ...

The addition of atezolizumab to neoadjuvant chemotherapy failed to significantly improve event-free survival in patients with ...

Dr Michelle Melisko discusses the challenging aspects involved in decision-making around screening for brain metastasis in ...

Recent cancer treatment breakthroughs include FDA approvals for zenocutuzumab and durvalumab, and sacituzumab tirumotecan gained breakthrough therapy status. In addition, sonodynamic therapy shows ...

Kazia Therapeutics ( (KZIA) ) has provided an announcement.

Gratitude is actively practiced, even amidst personal losses and living with metastatic cancer, highlighting its importance ...

The FDA orphan drug designation offers benefits such as tax credits and assistance in the drug development process.

Verition Fund Management LLC acquired a new position in shares of Nuvalent, Inc. (NASDAQ:NUVL – Free Report) during the 3rd ...

Nuvalent, Inc. has promising drugs, zidesamtinib and NVL-655, targeting NSCLC with encouraging data. Read why NUVL stock is a ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window HOUSTON -- Two-thirds of patients with PI3K-mutant brain metastases responded to the maximum tolerated dose (MTD ...